Jazz Pharmaceuticals jobs

Specialty Sales Consultant, Charleston SC Charleston, South Carolina posted: Posted 30+ Days Ago

Senior Oncology Account Manager, Hematology 4 Locations posted: Posted 23 Days Ago

Principal, Data Engineering (Remote) Philadelphia, Pennsylvania posted: Posted 30+ Days Ago

Specialty Sales Consultant Iowa (Remote) 2 Locations posted: Posted 30+ Days Ago

Senior Oncology Account Manager- Philadelphia, PA & Southern New Jersey (Remote) 2 Locations posted: Posted 24 Days Ago

Senior Oncology Account Manager - Northern New Jersey 2 Locations posted: Posted 10 Days Ago

Associate Director, Transactional Monitoring, Data Analytics & Risk Assessment US - Home-Based - PA posted: Posted 8 Days Ago

Senior Manager, Pipeline Innovation 3 Locations posted: Posted 16 Days Ago

VP, Clinical Development - Infectious Disease Frederick, Maryland or Berkeley Heights, New Jersey Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position

Director, Medical Safety Scientist 3 Locations posted: Posted 7 Days Ago

Research Scientist US - Site-Based - Durham posted: Posted Today

Vice President, Pharmaceutical Development Watertown, MA Who we are: Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients' lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston's top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (formerly Twitter) or LinkedIn . How we work: - PIONEER : We are courageous, resilient and rigorous in our mission to improve patients' lives through our revolutionary degrader medicines. - COLLABORATE : We value trust + transparency from everyone. Our goals are shared, our decisions data-driven and our camaraderie genuine. - BELONG : We recognize our differences, inviting curiosity and inclusivity, so that our people are valued, seen, and heard. How you'll make an impact: - Define and lead the company's pharmaceutical development strategy across the portfolio, ensuring alignment with corporate priorities and development timelines - Provide strategic leadership for preformulation, biopharmaceutics, and formulation development activities supporting discovery, preclinical, and clinical-stage programs - Champion innovation in formulation sciences and enabling technologies to

Exec Dir, Product Marketing 6 Locations posted: Posted 3 Days Ago

Vice President, Senior Counsel – Commercial and Compliance US Remote “Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is headquartered in Radnor, Pennsylvania. For more information, please visit https://mineralystx.com . Follow Mineralys on LinkedIn, Twitter and Bluesky” Mineralys is a fully remote company. Vice President, Senior Counsel - Commercial & Compliance Mineralys is seeking an energetic, versatile, and highly driven attorney to serve as Senior Counsel, Commercial and Compliance. This individual will serve as a strategic legal partner to the Commercial and Medical Affairs teams and will report directly to the Chief Legal Officer. Prior experience assisting with commercial launch is essential. Key Responsibilities Commercial Legal Leadership - Serve as the primary legal advisor to the Commercial and Medical Affairs teams - Provide strategic counsel across pre-launch and launch activities, balancing legal risk with business objectives - Support commercialization readiness, including promotional strategy, market access, patient services, and distribution models - Draft, review, and negotiate a wide range of commercial agreements (e.g., vendors, patient support programs, speaker programs, distribution, market access) - Lead legal review of promotional and medical materials through MLR/PRC processes - Advise on interactions with HCPs, patients, payors, specialty pharmacies, and government entities - Support commercial and medical affairs activities, including speaker programs, advisory boards,

Vice President, Regulatory Affairs Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Vice President, Regulatory Affairs will manage several key U.S. based regulatory functions and report to the SVP of Regulatory and Quality. The position is responsible for expanding and leading a large, high functioning regulatory group and ensuring global alignment. - Provide ethical and mission-driven leadership of the Regulatory Affairs functions. Embody and practice the company's mission-driven culture. Ensure that our core values guide our strategic vision and our day-to-day decision making. - Provide a vision for the Regulatory Affairs organization and develop a plan to achieve it. Design and rapidly scale a group to meets the needs of an explosive pipeline in areas of high unmet medical need and intense industry competition. - Influence decision-making of senior leadership and ensure globally aligned regulatory decision-making. - Collaborate closely and form effective relationships with other functional heads and regional counterparts to ensure high quality,

Senior Manager, Real Word Evidence Philadelphia, Pennsylvania posted: Posted 30+ Days Ago

Vice President, Analytical Development & Quality Control Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a strategic and execution-driven Vice President, Analytical Development & Quality Control (ADQC) to lead the vision, strategy, and execution of analytical development and QC across our growing portfolio. Reporting to the Senior Vice President, Pharmaceutical Development & Manufacturing, this executive will build and scale a phase-appropriate, forward-looking analytical organization that enables rapid development of small molecule programs while positioning the company for late-stage development and global commercialization. As a key member of the PDM leadership team, this role will shape analytical strategy at the enterprise level, ensuring robust control strategies, regulatory readiness, and operational excellence across internal and external networks. Responsibilities: Strategic & Organizational Leadership - Define and drive the enterprise-wide analytical development and QC strategy aligned with portfolio and corporate objectives. - Build, lead, and scale a high-performing ADQC organization to support a multi-asset oncology pipeline.

Vice President, Commercial Manufacturing Operations Remote Vera Therapeutics is a biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics' mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics' lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating the development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868. For more information, please visit www.veratx.com . Our values are the cornerstone of our culture. Our values inspire us every day and guide everything we do-from how we hire great people, to advancing our mission together, to achieving our ultimate goal to improve medical treatment for patients suffering from immunological diseases. Position Summary: The Vice President, Manufacturing Operations will report

Director, Medical Affairs (Epilepsy) Boston | [Hybrid] | Remote

Director, Real World Evidence US - Home-Based posted: Posted 25 Days Ago

Senior Accountant, Finance - 12 Month FTC 2 Locations posted: Posted 28 Days Ago

Associate Director, Early Stage Analytical Development 2 Locations posted: Posted 30+ Days Ago

Vice President, Talent Management US Remote “Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is headquartered in Radnor, Pennsylvania. For more information, please visit https://mineralystx.com . Follow Mineralys on LinkedIn, Twitter and Bluesky” Mineralys is a fully remote company. Vice President, Talent Management Position Summary The Vice President, Talent Management is a transformational leader who will design, build and lead a best-in-class, full-lifecycle talent organization at a pivotal moment in our company's history. As we transition from a development-stage company to a commercial enterprise, this leader will serve as the architect of our talent strategy - ensuring we attract, develop, engage and retain the exceptional people needed to bring life-changing therapies to patients. This is a role for a builder - someone who thrives in ambiguity, can construct scalable systems from the ground up and brings the vision, energy and operational excellence to transform talent into a true competitive advantage. The VP, Talent will be a trusted advisor to the organization and a champion of our culture and values across every dimension of the employee experience. Mineralys operates a hub-based remote model, with organizational anchors in Philadelphia, Boston and Boulder. This leader must be equally fluent in building distributed workforce practices and leveraging our hubs as cultural and

Vice President Quality Assurance Boston, Massachusetts Olema Oncology is dedicated to developing better medicines for breast cancer and beyond. Our lead program, palazestrant (OP-1250), is a complete estrogen receptor antagonist (CERAN) currently in development for metastatic breast cancer with blockbuster potential as a monotherapy and in combination in ER+/HER2- metastatic breast cancer. Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with best-in-class potential. Our scientific breakthroughs are accelerated through the ways in which we fearlessly support, motivate, and challenge one another. At Olema, we know that when we put people first, our work becomes second to none. If you're ready to join us at the edge of something unstoppable, let's make a profound impact together for our patients, for your career, for what's beyond . You can view our latest corporate deck and other presentations here . About the Role >>> Vice President, Quality Assurance The Vice President, Quality Assurance serves as the senior leader accountable for defining and driving Olema's global quality strategy, systems, and governance across the full product lifecycle, including clinical development, manufacturing, pharmacovigilance, and commercial. This leader is the primary voice of Quality at the executive level and ensures a phase-appropriate, risk-based approach to quality that reflects the needs of oncology drug development, where patient safety, data integrity, and speed are critical. Operating with appropriate independence, this role partners cross-functionally and leads an established Quality leadership team across GCP, GMP, and GPV - aligning priorities, strengthening execution, and ensuring inspection readiness as Olema advances